Companies ›Healthcare ›BVS.O

BVS.O — NASDAQ Diversified Medical Equipment & Supplies

Bioventus Inc

$13,73

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

9,4 %

ROE

12,3 %

Net margin

4,0 %

Debt / equity

1,65

Beta

—

52w range

—

Volume

512

Day range

$8,88–$9,16

Prev close

$9,02

Open

$9,05

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

The company maintains a debt-to-equity ratio of 1.65, indicating a moderate reliance on debt financing, while its current ratio of 1.7 suggests adequate short-term liquidity to cover obligations. Free cash flow of $71.7 million and operating cash flow of $74.7 million support operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of 12.35%, outperforming the industry median of 9.8%, but return on assets of 3.33% lags behind the sector average of 5.1%, indicating underutilization of asset base. Gross margin of 68.3% aligns with industry norms, but operating margin of 9.4% is below the 12.7% median, pointing to cost management challenges. Revenue is concentrated in the United States, with 82% of total revenue derived domestically, and the remaining 18% from international markets. The company operates in a single reportable segment focused on orthobiologics and regenerative medicine. Outlook for FY2025 shows revenue growth of 6.2% year-over-year, driven by new product launches and expanded distribution. However, operating income is projected to decline by 4.1% due to

Business. Bioventus Inc (BVS.O) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including medical devices and consumables. Bioventus is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

American Century Investment Management, Inc.

largest disclosed fund holder

Profitability→

12,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning BVS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to BVS.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Bioventus Inc (BVS.O) is a healthcare services and equipment company operating in the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including medical devices and consumables. Bioventus is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

Profitability metrics show a return on equity of 12.35%, outperforming the industry median of 9.8%, but return on assets of 3.33% lags behind the sector average of 5.1%, indicating underutilization of asset base. Gross margin of 68.3% aligns with industry norms, but operating margin of 9.4% is below the 12.7% median, pointing to cost management challenges.

Revenue is concentrated in the United States, with 82% of total revenue derived domestically, and the remaining 18% from international markets. The company operates in a single reportable segment focused on orthobiologics and regenerative medicine.

Outlook for FY2025 shows revenue growth of 6.2% year-over-year, driven by new product launches and expanded distribution. However, operating income is projected to decline by 4.1% due to increased R&D and marketing expenses. Over the next fiscal year, revenue is expected to rise by 4.8%, with net income growth of 2.3%.

Risk assessment highlights medium liquidity risk due to negative net cash and a high debt-to-equity ratio. Dilution risk is low, with no near-term share issuance expected, though the company has $303.6 million in long-term debt that could necessitate future financing. Regulatory and geopolitical risks remain moderate, with no material exposure to high-risk jurisdictions.

Recent 10-K filings disclose ongoing litigation related to product liability and patent disputes, with no material impact on financial position. A Q4 earnings call transcript noted supply chain bottlenecks affecting inventory turnover, though management expects resolution by Q2 2025.

Key takeaways

Bioventus generates strong free cash flow but faces liquidity constraints due to high debt.
Return on equity outperforms industry peers, but asset efficiency lags.
Domestic revenue concentration and single-segment exposure limit diversification.
Near-term growth is modest, with operating income pressured by rising expenses.
Low dilution risk contrasts with medium liquidity and regulatory risks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$13,73

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$184.1M

Net cashⓘ

-$252.3M

Current ratioⓘ

1.7

Debt / equityⓘ

1.6

ROAⓘ

3.3%

ROEⓘ

12.3%

Cash conversionⓘ

328.0%

CapEx / revenueⓘ

-0.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%